AstraZeneca says U.S. trial data shows 79% efficacy against symptomatic COVID-19

AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the company announced Monday.

View original article here Source